drugset / Trial / NCT07247656
The Efficacy and Safety of Empagliflozin - Linagliptin and Empagliflozin- Metformin Therapy in Reduction of Body Weight in Type 2 Diabetic Patients .
RandomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical trial is - Comparison of Empagliflozin - Linagliptin with Empagliflozin - Metformin combination therapy in reduction of body weight in T2DM Patients and it included 200 diabetic subjects with total study period of 12 weeks and individual study period of 4 weeks .
Timeline
- Start
- 2022-12-01
- Primary completion
- 2023-03-01
- Completion
- 2023-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Linagliptin | Small molecule | 5 mg | Oral |
| Comparator | Metformin | Small molecule | 500 mg | — |
| Comparator | Empagliflozin | Small molecule | 10 mg | Oral |
| Comparator | Empagliflozin | Small molecule | 10 mg | — |